Poster and Platform Presentations -
Parkinson's Disease Center and Movement Disorders Clinic

Click on the Expand plus sign sign to list the poster and platform presentations by year. Then click on the link to view that presentation.

2016

Collapse All | Expand All

 

    Movement Disorder Society (MDS)
    20th International Congress of Parkinson's Disease and Movement Disorders in Berlin, Germany (June 19-23, 2016)
    • Understanding, predicting, and preventing falls in progressive supranuclear palsy.

      Bluett BR, Litvan I, Cheng S, Juncos J, Bordelon Y, Riley DE, et al.

    • A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD).

      Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo W, LeDoux MS, et al.

    • Objectives of the MDS rare movement disorders study group.

      Gatto EM, Albanese A, Bathia K, Cardoso F, Cesarini M, Chade A, et al.

    • The National Parkinson Foundation mentoring and networking program: Phase I the process.

      Hunter CB, Palmentera PR, Vernon B, Silver A, Arney K, Fleisher J, et al.

    • A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome.

      Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy TK, Shprecher D, et al.

    • Predictors of onabotulinumtoxinA treatment response in patients with cervical dystonia.

      Jankovic J, Marc S, Aubrey A

    • Apraclonidine in blepharospasm.

      Jankovic J, Vijayakumar D, Wijemanne S

    • One to 40 years later: Delayed effects of brain radiation presenting as parkinsonism.

      Jimenez-Shahed J, Itin I, Mehanna R

    • Globus pallidus interna oscillatory activity differentiates tics from voluntary movements and the Parkinsonian resting state.

      Jimenez-Shahed J, Telkes I, Viswanathan A, Ince NF

    • Apraclonidine in the treatment of ptosis.

      Wijemanne S, Vijayakumar D, Jankovic J

    American Academy of Neurology (AAN)
    68th Annual Meeting in Vancouver, BC, Canada (April 15-21, 2016)
    • Success of targeting rationale in deep brain stimulation for Parkinson's disease.

      Farcas A, Jimenez Shahed J

    • A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome.

      Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, et al.

    • Safety profile of unblinded internal pallidal deep brain stimulation for medically refractory Tourette syndrome.

      Niemann N, Strutt A, Viswanathan A, Jimenez Shahed J

    • Paradoxical worsening dystonia after deep brain stimulation in a patient with neurodegeneration with brain iron accumulation.

      Tarakad A, Jimenez Shahed J

2015

Collapse All | Expand All

 

    American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
    62nd Annual Meeting in Honolulu, Hawaii (Oct. 28-31, 2015)
    • Dual antibody positivity in Myasthenia gravis.

      Jindal P, De Sousa E, Refai S, Vohra A

    American Neurological Association (ANA)
    140th Annual Meeting in Chicago, Ill. (Sept. 27-29, 2015)
    • Differentiation of mild cognitive impairment (MCI) subtypes using sleep questionnaires: Amnestic MCI versus MCI preceding dementia with Lewy bodies.

      Jindal P, Carlson B, Wenger M, Carlson J, Hershey L

    Movement Disorder Society (MDS)
    19th International Congress of Parkinson's Disease and Movement Disorders in San Diego, Calif. (June 14-18, 2015)
    • A randomized controlled trial of telemedicine for Parkinson's disease (Connect.Parkinson) in the United States: Interim assessment of investigator and participant experiences.

      Achey MA, Beck CA, Beran DB, Boyd CM, Schmidt PN, Willis AW, et al.

    • XCiDaBLE: Observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the USA.

      Fernandez HH, Jankovic J, Pagan F, Greeley D, Sethi K, Verma A

    • Progressive supranuclear palsy and statin use.

      Fuentes A, Standaert D, Marras C, Riley D, Hall D, Kluger B, et al.

    • DBS experience at a tertiary care referral center.

      Jimenez-Shahed J, Keller J, Hunter C, Jankovic J

    • American multiple system atrophy natural history study.

      Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, et al.

    • Cervical dystonia and work productivity: Results from the cervical dystonia patient registry for the observation of onabotulinumtoxinA efficacy.

      Molho ES, Stacy M, Gillard P, Charles D, Adler CH, Jankovic J, et al.

    • Dystonia-spasticity in a patient with a novel SLC25A12 mutation.

      Parnes M, Robak L, Shulman JM, Stocco A, Jankovic J

    • Clinical characteristics of tetrabenazine-induced parkinsonism.

      Shah D, Jimenez-Shahed J

    • Clinical utility of apraclonidine in ptosis.

      Wijemanne S, Jankovic J

    American Academy of Neurology (AAN)
    67th Annual Meeting in Washington, DC (April 18-25, 2015)
    • Reliability of the severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2).
      [Oral Presentation]

      Comella C, Perlmutter J, Jinnah H, Factor S, Goetz C, Adler C, et al.

    • XCiDaBLE: An observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Final results from the blepharospasm cohort.

      Fernandez HH, Jankovic J, Holds J, Lin D, Burns J, Sethi K, et al.

    • The impact of cervical dystonia on work productivity: An analysis from the CD Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (CD PROBE).

      Molho E, Stacy M, Gillard P, Charles P, Adler C, Jankovic J, et al.

    • Dystonia-spasticity in a patient with a novel SLC25A12 mutation.

      Parnes M, Robak L, Shulman J, Stocco A, Jankovic J

    • SUNCT responding to botulinum toxin.

      Wijemanne S, Jankovic J

<2014

Collapse All | Expand All